As of January 22, 2025, Longeveron (LGVN) has a market cap of $25.519 million USD. According to our data, Longeveron is ranked No.8510 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $25.52 M |
10.47%
|
Dec 31, 2024 | $23.10 M |
-87.28%
|
Dec 29, 2023 | $0.18 B |
-57.76%
|
Dec 30, 2022 | $0.43 B |
-73.32%
|
Dec 31, 2021 | $1.61 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Mesoblast
MESO
|
$2.03 B |
0.000 M
|
Australia
|
Capricor Therapeutics
CAPR
|
$0.68 B |
0.000 M
|
USA
|
Lineage Cell Therapeutics
LCTX
|
$0.15 B |
-0.000 M
|
USA
|
BrainStorm Cell Therapeutics
BCLI
|
$12.15 M |
0.000 M
|
USA
|
Vericel
VCEL
|
$2.89 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Market Cap | = | LGVN Stock Price | * | LGVN Shares Outstanding |
= | $1.72 | * | 13.35 M | |
= | $25.52 M |